Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering

Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced the closing of a public offering on September 19, 2022, of 4,800,000 shares at $26.00 per share, raising $124.8 million in gross proceeds. The offering included an option for underwriters to purchase an additional 720,000 shares. Proceeds will fund the global commercialization of IMCIVREE for specific obesity types and support the clinical development of setmelanotide for hypothalamic obesity and various trials. Cowen, Stifel, and Wells Fargo acted as joint book-running managers for this offering.

Positive

• Raised $124.8 million for commercialization and clinical development.
• Funding supports specific obesity treatments and ongoing trials.

Negative

• Potential dilution of shares due to the offering.

BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor pathway (MC4R) diseases, today announced the closing of its public offering of 4,800,000 shares of its common stock at a public offering price of $26.00 per share on September 19, 2022. The aggregate gross proceeds to Rhythm from the offering were $124.8 million, before underwriting discounts and commissions, and offering expenses. In addition, Rhythm has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of its common stock at the public offering price, less the underwriting discount and commission. All of the shares in the offering were offered by Rhythm.

Rhythm intends to use the net proceeds from this offering to advance global commercialization of IMCIVREE for obesity due to POMC, PCSK1 or LEPR deficiency and BBS, to advance clinical development of setmelanotide in hypothalamic obesity, as well as its EMANATE, DAYBREAK and weekly formulation trials, and for working capital and general corporate purposes.

Cowen, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. Ladenburg Thalmann is acting as manager for the offering.

The offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed by Rhythm with the Securities and Exchange Commission (“SEC”) on November 2, 2021 and declared effective by the SEC on November 15, 2021. A preliminary prospectus supplement relating to the offering was filed with the SEC on September 14, 2022. The final prospectus supplement relating to the offering was filed with the SEC on September 15, 2022. Copies of the final prospectus supplement relating to the offering may be obtained from: Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at 415-364-2720 or by email at syndprospectus@stifel.com; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York 10001, at 833-690-2713 or email a request to cmclientsupport@wellsfargo.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the intended use of proceeds from the offering. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, risks associated with general economic and market conditions and the other important factors discussed under the caption “Risk Factors” in the prospectus supplement related to the offering, our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022 and our other filings with the SEC. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this press release or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise.

Company Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

FAQ

What was the purpose of Rhythm Pharmaceuticals' recent stock offering?

The stock offering aimed to raise funds for advancing the commercialization of IMCIVREE and clinical development of setmelanotide, among other corporate purposes.

How much did Rhythm Pharmaceuticals raise from the recent offering?

Rhythm Pharmaceuticals raised $124.8 million in gross proceeds from the offering of 4,800,000 shares.

What are the risks associated with the stock offering by Rhythm Pharmaceuticals?

The risks include potential dilution of shares and market fluctuations that may affect the stock price.

When did Rhythm Pharmaceuticals complete its stock offering?

The stock offering was completed on September 19, 2022.

Who managed the stock offering for Rhythm Pharmaceuticals?

The offering was managed by Cowen, Stifel, and Wells Fargo Securities.